



Approved for use through 07/30/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/584,207
Filing Date	June 23, 2006
First Named Inventor	Colgan et al.
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	MTS5USA

Sheet 1 of 9

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	AL	WO-98/10291-A1	03-12-1998	BYRJALSEN et al.		
	AM	WO-99/63115-A2	12-09-1999	SCHNEIDER et al.		
	AN	WO-99/63116-A2	12-09-1999	SCHNEIDER et al.		
	AO	WO-01/62959-A2	08-30-2001	BALLAN et al.		
	AP	WO-01/92338-A1	12-06-2001	MUTTER et al.		
	AQ	WO-00/16805-A1	03-30-2000	ALI et al.		

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	2	of	9	Attorney Docket Number	MTS5USA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR	AGBOOLA et al., "Costs and benefits of routine follow-up after curative treatment for endometrial cancer", Can. Med. Assoc. J., 157(7):879-886 (October 1, 1997)	
	AS	ANDERSEN et al., "Functional genomics by mass spectrometry", FEBS Letters, 480:25-31 (August 25, 2000)	
	AT	ARCURI et al., "Macrophage migration inhibitory factor in the human endometrium: expression and localization during the menstrual cycle and early pregnancy", Biol. of Reproduction, 64:1200-1205 (April 2001)	
	AU	ATHANASAS-PLATIS et al., "Early pregnancy factor is required at two important stages of embryonic development in the mouse", AJRJ, 43:223-233 (April 2000)	
	AV	BACHER et al., "Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme", Am. J. Pathol., 162(1):11-17 (January 2003)	
	AW	BAGGERLY et al., "Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments", Bioinformatics, 20(5):777-785 (March 22, 2004, Epub Date Jan 29, 2004)	
	AX	BATORFI et al., "Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells", Gynecologic Oncology, 88:424-428 (March 2003)	
	AY	BERKOVA et al., "Haptoglobin is present in human endometrium and shows elevated levels in the decidua during pregnancy", Mol. Human Reprod., 7(8):747-754 (August 2001)	
	AZ	BERNSTEIN et al., "Tamoxifen Therapy for Breast Cancer and Endometrial Risk", J. Natl. Cancer. Inst., 91(19):1654-1662 (October 6, 1999)	
	AAR	BHARDWAJ et al., "The calcium-binding proteins MRP8 and MRP14 form a membrane-associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions", Eur. J. Immunol., 22:1891-1897 (July 1992)	
	AAS	BIGONNESSE et al., "Triphasic expression of interleukin-1 receptor type I in human endometrium throughout the menstrual cycle of fertile women and women with unexplained infertility", Fertility and Sterility, 75(1):79-87 (January 2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	3	of	9	Attorney Docket Number	MTS5USA

	AAT	BLAXALL et al., "Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF1) and Hu antigen R (HuR) in neoplastic lung tissue", Mol. Carcinogenesis, 28:76-83 (June 2000)	
	AAU	BORDMANN et al., "MRP 8/14 as marker for Plasmodium falciparum-induced malaria episodes in individuals in a holoendemic area", Clin. Diag. Lab Immunol., 4(4):435-439 (July 1997)	
	AAX	BUNDRED, "Prognostic and predictive factors in breast cancer", Cancer Treatment Rev., 27:137-142 (June 2001)	
	AAY	BURKHARDT et al., "An increase in Myeloid-related protein serum levels precedes acute renal allograft rejection", J. Am. Soc. Nephrol., 12(9):1947-1957 (September 2001)	
	AAZ	CAMPA et al., "Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential molecular targets in non-small cell lung cancer", Cancer Res., 63:1652-1656 (April 1, 2003)	
	BR	CAPPELLO et al., "Ten kilodalton heat shock protein (HSP10) is overexpressed during carcinogenesis of large bowel and uterine exocervix", Cancer. Lett., 196:35-41 (June 30, 2003)	
	BS	CARSON et al., "Changes in gene expression during the early to mid-luteal (receptive phase) transition in human endometrium detected by high-density microarray screening", Mol. Human Rep. 8(9):871-879 (September 2002)	
	BT	CAVANAGH et al., "The purification of early-pregnancy factor to homogeneity from human platelets and identification as chaperonin 10", Eur. J. Biochem., 222:551-560 (June 1, 1994)	
	BU	CHAMBERS et al., "Proteomics: a new approach to the study of disease", J. Pathol., 192:280-288 (November 2000)	
	BV	CHANG et al., "Augmented expression of peroxiredoxin I in lung cancer", Biochem. Biophys. Res. Comm., 289:507-512 (November 30, 2001)	
	BW	CHAURAND et al., "Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry", Proteomics 2001, 1(10):1320-1326 (October 2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	4	of	9	Attorney Docket Number	MTS5USA

	BX	CHECK, E., "Running before we can walk?", Nature, 429:496-497 (June 3, 2004)	
	BY	CHEN et al., "Proteomic analysis of lung adenocarcinomas: identification of a highly expressed set of proteins in tumors", Clin. Cancer Res., 8:2298-2305 (July 2002)	
	BZ	CHOI et al., "Creatine kinase B is a target molecule of reactive oxygen species in cervical cancer", Mol. Cells, 12(3):412-417 (December 31, 2001)	
	BBR	CORNFORD et al., "Heat shock protein expression independently predicts clinical outcome in prostate cancer", Cancer Res., 60:7099-7105 (December 15, 2000)	
	BBS	COTTINGHAM et al., "Clinical proteomics: are we there yet?", Analytical Chem., 472A-476A (November 1, 2003)	
	BBT	CRNOGORAC-JURCEVIC et al., "Expression profiling of microdissected pancreatic adenocarcinomas", Oncogene, 21(29):4587-4594 (July 4, 2002)	
	BBU	DeSOUZA et al., "Proteomic analysis of the proliferative and secretory phases of the human endometrium: protein identification and differential protein expression", Proteomics, 5:270-281 (January 2005)	
	BBV	DIAMANDIS, "Mass spectrometry as a diagnostic and a cancer biomarker discover tool", Mol. & Cell. Proteomics, 3:367-378 (April 2004; e-pub: February 28, 2004)	
	BBW	DIAMANDIS, Correspondence in The Lancet, 360:170 (July 13, 2002)	
	BBX	DIAMANDIS, "Re: Serum proteomic patterns for detection of prostate cancer", Correspondence in J. Natl. Cancer Inst., 95(6):489-491 (March 19, 2003)	
	BBY	DIAMANDIS, "Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?", Clin. Chem., 49(8):1272-1278 (August 2003)	
	BBZ	DONATO, "S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles", IJBCB, 33:637-668 (July 2001)	
	CR	DUCHEN, "Section III: Mitochondria, β -Cell function, and type 2 diabetes. Roles of mitochondria in health and disease", Diabetes, 53(Suppl. 1):S96-S102 (February 2004)	
	CS	DUFFY, "Clinical uses of tumor markers: A critical review", Crit. Rev. Clin. Lab. Sci, 38(3):225-262 (June, 2001)	
	CT	FANJUL et al., "Presence of MRP8 and MRP14 in pancreatic cell lines: differential expression and localization in CFPAC-1 cells", Amer. Physiol. Soc., 268(5 Pt 1):C1241-1251 (May 1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	5	of	9	Attorney Docket Number	MTS5USA

	CU	FREEMANTLE et al., "Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2", Gene, 291:17-27 (May 29, 2002)	
	CV	FUJIWAKI et al., "Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase", Virchows Arch., 332:672-677 (2003; e-pub: August 9, 2003)	
	CW	GEBHARDT et al., "Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis", Oncogene, 21:4266-4276 (June 20, 2002)	
	CX	GENG et al., "Signature-peptide approach to detecting proteins in complex mixtures", J. Chromat. A, 870:295-313 (February 18, 2000)	
	CY	GOSHE et al., "Phosphoprotein isotope-coded affinity tag approach for isolating and quantitating phosphopeptides in proteome-wide analyses", Anal. Chem., 73:2578-2586 (June 1, 2001)	
	CZ	GOUBLE et al., "A new player in oncogenesis: AUF1/hnRNPd overexpression leads to tumorigenesis in transgenic mice", Cancer Res., 62:1489-1495 (March 1, 2002)	
	CCR	GUO et al., "A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma", Proteomics, 5:1953-1966 (May 2005)	
	CCT	GYGI et al., "Quantitative analysis of complex protein mixtures using isotope-coded affinity tags", Nature Biotechnol., 17:994-999 (October 1999)	
	CCU	HATHOUT et al., "Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan", J. Proteome Res., 1:435-442 (2002; e-pub: August 13, 2002)	
	CCV	HE et al., "Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics", Proteomics, 4:271-278, (January 2004)	
	CCW	HERRMANN et al., "Enzymology of human myometrium: variations related to the hormonal milieu", Arch. Gynecol., 240:233-240 (1987)	
	CCX	HONGISTO et al., "Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3", Mol. Cel. Biol., 23(17):6027-6036 (September 2003)	
	CCY	HUNTER et al., "High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14", J. Biol. Chem., 273(20):12427-12435 (May 15, 1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	5	of	9	Attorney Docket Number	MTS5USA

CU	FREEMANTLE et al., "Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2", Gene, 291:17-27 (May 29, 2002)	
CV	FUJIWAKI et al., "Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase", Virchows Arch., 332:672-677 (2003; e-pub: August 9, 2003)	
CW	GEBHARDT et al., "Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis", Oncogene, 21:4266-4276 (June 20, 2002)	
CX	GENG et al., "Signature-peptide approach to detecting proteins in complex mixtures", J. Chromat. A, 870:295-313 (February 18, 2000)	
CY	GOSHE et al., "Phosphoprotein isotope-coded affinity tag approach for isolating and quantitating phosphopeptides in proteome-wide analyses", Anal. Chem., 73:2578-2586 (June 1, 2001)	
CZ	GOUBLE et al., "A new player in oncogenesis: AUF1/hnRNP overexpression leads to tumorigenesis in transgenic mice", Cancer Res., 62:1489-1495 (March 1, 2002)	
CCR	GUO et al., "A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma", Proteomics, 5:1953-1966 (May 2005)	
CCS	GRADY et al., "Endometrial Cancer" in Cancer Epidemiology and Prevention, 2 nd Ed., 1999, Schottenfeld et al., Eds., Saunders Publishing, New York, NY: 1058-1089	
CCT	GYGI et al., "Quantitative analysis of complex protein mixtures using isotope-coded affinity tags", Nature Biotechnol., 17:994-999 (October 1999)	
CCU	HATHOUT et al., "Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan", J. Proteome Res., 1:435-442 (2002; e-pub: August 13, 2002)	
CCV	HE et al., "Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics", Proteomics, 4:271-278, (January 2004)	
CCW	HERRMANN et al., "Enzymology of human myometrium: variations related to the hormonal milieu", Arch. Gynecol., 240:233-240 (1987)	
CCX	HONGISTO et al., "Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3", Mol. Cel. Biol., 23(17):6027-6036 (September 2003)	
CCY	HUNTER et al., "High level expression and dimer characterization of the S100 EF-hand proteins, migration inhibitory factor-related proteins 8 and 14", J. Biol. Chem., 273(20):12427-12435 (May 15, 1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	6	of	9	Attorney Docket Number	MTS5USA

	CCZ	KERKHOFF et al., "Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9)", BBA, 1448(2):200-211 (December 10, 1998)	
	DR	KLEIN et al., "Detection of Circulating Tumor Cells by Cytokeratin 20 in the Blood of Patients with Endometrial Carcinoma", Gynecol. Oncol. 78:352-355 (September, 2000)	
	DS	LIN et al., "Inhibition of p53 transcriptional activity by the S100B calcium-binding protein", J. Biol. Chem., 276(37):35037-35041 (September 14, 2001)	
	DT	LIN et al., "Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells", J. of Biol. Chem., 279(32):34071-34077 (August 6, 2004)	
	DU	LUNDY et al., "Identification of MRP-8 (calgranulin A) as a major responsive protein in chronic periodontitis", J. Pathol., 192(4):540-4 (December 2000)	
	DV	MAHUTTE et al., "Elevations in peritoneal fluid macrophage migration inhibitory factor are independent of the depth of invasion or state of endometriosis", Fert. and Steril., 82(1):97-101 (July 2004)	
	DW	MALDONADO et al., "Expression of transcription factors in endometrium during natural cycles", J. Assisted Reproduction and Genetics, 20(11):474-481 (November 2003)	
	DX	MARKERT et al., "Differential gene expression profiling in human brain tumors", Physiol. Genomics, 5:21-33 (February 2001)	
	DY	MUTTER et al., "Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation", Gyn. Oncol., 83:177-185 (November 2001)	
	DZ	NACKEN et al., "S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity", Microsc. Res. Tec., 60:569-580 (April 15, 2003)	
	DDR	NEJJARI et al., "Inhibition of proprotein convertases enhances cell migration and metastases development of human colon carcinoma cells in a rat model", Am. J. Pathol., 164 (6):1925-1933 (June 2004)	
	DDS	ODINK et al., "Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis", Nature, 330:80-82, (November 5-11, 1987)	
	DDT	OTA et al., "Distribution of heat shock proteins in eutopic and ectopic endometrium in endometriosis and adenomyosis", Fertility & Sterility, 68(1):23-28 (July 1997)	
	DDU	PAWELETZ et al., "Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip", Drug Devel. Res., 49:34-42 (2000)	
	DDV	PENG et al., "Proteomics: the move to mixtures", J. Mass Spectrometry, 36:1083-1091 (2001; e-pub: October 3, 2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	7	of	9	Attorney Docket Number	MTS5USA

	DDW	PETRICOIN et al., "Use of proteomic patterns in serum to identify ovarian cancer", The Lancet, 359:572-577 (February 16, 2002)	
	DDX	PETRICOIN et al., "Serum proteomic patterns for detection of prostate cancer", J. Natl. Cancer Inst., 94(20):1576-1578 (October 16, 2002)	
	DDY	QUINN et al., "Early pregnancy factor in liver regeneration after partial hepatectomy in rats: relationship with chaperonin 10", Hepatology, 20(5):1294-1302 (November 1994)	
	DDZ	QUINN et al., "Effect of monoclonal antibodies to early pregnancy factor (EPF) on the in vivo growth of transplantable murine tumours", Cancer Immunol. Immunother., 34:265-271 (1992)	
	ER	RAUTAJOKI et al., "Proteome characterization of human T helper 1 and 2 cells", Proteomics, 4:84-92 (January 2004)	
	ES	REN et al., "Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma", Int. J. Cancer, 107:22-29 (October 20, 2003)	
	ET	ROSE, "Endometrial Cancer", New. Engl. J. Med., 335(9):640-649 (August 29, 1996)	
	EU	ROSSEL et al., "Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma", Urol. Res., 19:361-366 (1991)	
	EV	RYU et al., "The proteomics approach to find biomarkers in gastric cancer", J. Korean Med. Sci., 18:505-509 (August 2003)	
	EW	SAITOH et al., "Molecular cloning and expression of proto-oncogene FRAT1 in human cancer", Int. J. Oncology, 20:785-789 (April 2002)	
	EX	SCHLUESENER et al., "Widespread expression of MRP8 and MRP14 in human cerebral malaria by microglial cells", Acta Neuropathol., 96:575-580 (December 1998)	
	EY	SCHMID et al., "Immunohistochemical demonstration of the calcium-binding proteins MRP8 and MRP14 and their heterodimer (27E10 antigen) in Crohn's disease", Human Pathol., 26(3):334-337, (March 1995)	
	EZ	SHIELDS et al., "Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways", J. Biol. Chem., 277(12):9790-9799 (March 22, 2002)	
	EER	SOMODEVILLA-TORRES et al., "Preparation and characterization of polyclonal antibodies against human chaperonin 10", Cell Stress & Chaperones, 5(1):14-20 (January 2000)	
	EES	SORACE et al., "A data review and re-assessment of ovarian cancer serum proteomic profiling", BMC Bioinformatics, 4:24 (June 9, 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	8	of	9	Attorney Docket Number	MTS5USA

EET	SRIVASTAVA et al., "Biomarkers for early detection of colon cancer", Clin. Cancer Res., 7:1118-1126 (May 2001)	
EEU	SHAARAWY et al., "Biomarkers of Intrinsic and Anti-Angiogenic Activity in Patients with Endometrial Hyperplasia and Endometrial Cancer", Acta. Oncol., 40(4):513-518 (2001)	
EEV	STULIK et al., "The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass", Electrophoresis, 20(4-5):1047-1054, (April-May 1999)	
EEW	SUGIYAMA et al., "Microdissection is essential for gene expression profiling of clinically resected cancer tissues", Anatomic Pathology, 117:109-116 (January 2002)	
EEX	SUN et al., "Role of imbalance between neutrophil elastase and α 1-antitrypsin in cancer development and progression", The Lancet Oncology, 5:182-190 (March 2004)	
EEY	TANAKA et al., "Human calgizzarin: one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern blot analysis", Cancer Lett., 89:195-200 (March 2, 1995)	
EEZ	TIBBLE et al., "Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma", Gut, 49:402-408 (September 2001)	
FR	VLAHOU et al., "Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine", Am. J. Pathol., 158(4):1491-1502 (April 2001)	
FS	VON WOLFF et al., "Glucose transporter proteins (GLUT) in human endometrium: expression, regulation, and function throughout the menstrual cycle and in early pregnancy", J. Clin. Endocrinol. & Metab., 88(8):3885-3892 (August 2003)	
FT	WRIGHT et al., "Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures", Prostate Cancer and Prostatic Diseases, 2:264-276 (December 1999)	
FU	WU et al., "Proteomics in cancer research", Int. J. Gynecol. Cancer, 12:409-423 (2002)	
FV	WULFKUHLE et al., "Proteomic applications for the early detection of cancer", Nature Reviews, 3:267-275 (April, 2003)	
FW	WULFKUHLE et al., "New approaches to proteomic analysis of breast cancer", Proteomics, 1:1205-1215 (October 2001)	
FX	ZHU et al., "Detection of Cancer-Specific Markers Amid Massive Mass Spectral Data", PNAS, 100:14666-14671 (2003; e-pub: December 1, 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Art Unit	unassigned
				Examiner Name	unassigned
Sheet	9	of	9	Attorney Docket Number	MTS5USA

	FY	ISSAQ, "Seldi-tof MS for Diagnostic Proteomics", Analytical Chem., 75(7):149A-155A (April 1, 2003)	
	FZ	YE, "Haptoglobin- α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry", Clin. Cancer Research, 9(8):2904-2911 (August 1, 2003)	
	FFR	KERKHOFF, "The regulatory role of MRP8 (S100A8) and MRP14 (S100A9) in the transendothelial migration of human leukocytes", Pathobiology, 67(5-6):230-232 (1999)	
	FFS	LICHTENFELS, "Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses", BBA, 1646(1-2):21-31 (March 21, 2003)	
	FFT	LÜGERING, "Serum 27E10 antigen: a new potential marker for staging HIV disease", Clin. Exp. Immunol., 101(2):249-253 (August 1995)	
	FFU	NISHIHARA, "Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis", Ann. NY Acad. Sci., 995:171-182 (May 2003)	
	FFV	WALCH, "Microdissection of tissue sections: application to the molecular genetic characterisation of premalignant lesions", Pathobiology, 68(1):9-17 (January/February 2000)	
	FFW	WILLIAMSON, "Diving Deeper into the Proteome: Next Generation ICAT reagents coupled with MDLC and High Throughput Mass Spectrometry", ASMS Proceedings, Poster Number WPA023 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.